Vorinostat is a histone deacetylase (HDAC) inhibitor. HDAC’s work by interfering with the cell’s ability to transmit genetic information from the DNA to cellular proteins.

400 mg orally once daily with food. May adjust dose to 300 mg daily for intolerance to therapy.

Indicated for treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL), who have progressive persistent or recurrent disease on or following two systemic therapies.

Side effects include diarrhea, fatigue, nausea, thrombocytopenia, anorexia, and dysgeusia. Pulmonary embolism and deep vein thrombosis have been reported. QT prolongation has been observed.

Avoid concomitant use with other HDAC inhibitors (e.g., valproic acid).

Monitor blood cell counts and chemistry tests, including potassium, magnesium, calcium, glucose, and serum creatinine, every two weeks during the first two months of therapy, and then monthly after that time.

Avoid use in pregnant women.

Capsules should not be opened or crushed.

Monitor prothrombin time and international normalized rate (INR) in patients receiving warfarin derivatives concurrently with vorinostat.